Project title: DEVELOPMENT OF IGF1R INHIBITORS AS ANTI-CANCER AGENTS

Company name : NOVOTYR THERAPEUTICS LTD.

LTD.

TECHNOLOGICAL FIELD
Biotechnology, Health Care,
Pharmaceutical

KEY WORDS
Tyrosine kinase, IGF1R, Apoptosis,
Tyrphostin, Small Molecule Drug

PROJECT SUMMARY
NovoTyr develops novel inhibitors of insulin-like growth factor
receptor (IGF1R), as drugs for the treatment of cancer and other
inflammatory disorders.

The ADVANTAGES of this strategy are:
* Specificity: In contrast to normal cells the viability of
various cancer cells is dependent on IGF1R activity. Therefore,
IGF1R inhibitors selectively affect tumor cells with little or no
toxic effects on normal cells.
* Target is expressed throughout the disease progression: IGF1R
inhibitors are developed to treat primary tumors as well as
advanced metastatic cancers.
* Synergistic effect with other modalities: IGF1R inhibitors will
be used as a mono-therapy or as chemosensitizers, when combined
with conventional chemotherapy or radiation. The latter strategy
is based on the observation that IGF1R activity is enhanced
during the development of resistance of cancer cells to
chemotherapy, and its inhibition sensitized these cells to
apoptosis (programmed cell death).
* Oral bioavailability: The inhibitors are proprietary novel
small molecules that will be administered orally.
* Unique approach: NovoTyr developed a unique IGF1R inhibitor,
which inhibits the tyrosine kinase activity of IGF1R, but as
opposed to other reported inhibitors, it also induces a
long-lasting decrease in the protein levels of IGF1R direct
substrate IRS1.

THE MARKET - According to a recent report published by BCC
research, the worldwide market for clinical use of kinase
inhibitors reached $4.63 billion in 2005 and will rise at an
average annual growth rate (AAGR) of 20.6% to $11.8 billion by
2010. The major disease application for kinase inhibitors is
oncology that comprises nearly 90% of kinase inhibitor sales in
2005 and is expected to grow at an AAGR of 21.5%.

ENTREPRENEURS
Dr. Hadas Reuveni -
CEO
Prof. Alexander Levitzki -
Founder, Director & CSO
Dr. Itzchak Angel
- Business development

PROJECT STATUS
NovoTyr was founded on March 2005.
During its first year of activity NovoTyr developed a novel
inhibitor of IGF1R, named NT52, with several unique features:
NT52 induces a specific reduction in the levels of IGF1R-direct
substrate IRS1 in cancer cells. This effect is long-lasting and
correlates with high anti-cancer activity in-vitro and in-vivo.
NT52 leads to the inhibition of the central anti-apoptotic
pathway in cancer cells, the activation of PKB, and to a
subsequent apoptosis of these cells. In-vivo experiments,
evaluating the efficacy of NT52 in human tumor-transplanted nude
mice, show significant and pronounced inhibitory effects in
prostate cancer (>80% inhibition) and ovarian cancer (>90%
inhibition) models.

A patent application protecting the novel inhibitors developed by
the company was submitted on December 4th, 2006.

COOPERATION REQUIRED
The Company is seeking a strategic partner for joined development
of selected leads.
----------------------------------------
TEL: 972-54-4659448, E-MAIL: hadas.reuveni@gmail.com

Request for more information, about this project.

Note - you have to be registered in this server to request information. If you haven't done so yet, please:
Register in this server and your requests will be forwarded to the developer, who will contact you directly

List of projects that you already requested more information about